References for: association

Full identifier: http://purl.org/np/RA-TRGdE8NIx2u6XXuidpkpZ6NSmlzceu4nLQD6XKGENo#association

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-21T07:40:41.205Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
the efficacy of paroxetine the effects of paroxetine in hospitalized depressed patients have not been adequately studied the efficacy of paroxetine in maintaining a response in major depressive disorder for up to 1 year was demonstrated in a placebo controlled trial see clinical pharmacology clinical trials nevertheless the physician who elects to use paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient the efficacy of paroxetine was established in two 12 week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the dsm iiir category of obsessive compulsive disorder see clinical pharmacology clinical trials obsessive compulsive disorder is characterized by recurrent and persistent ideas thoughts impulses or images obsessions that are ego dystonic and or repetitive purposeful and intentional behaviors compulsions that are recognized by the person as excessive or unreasonable long term maintenance of efficacy was demonstrated in a 6 month relapse prevention trial in this trial patients assigned to paroxetine showed a lower relapse rate compared to patients on placebo see clinical pharmacology clinical trials nevertheless the physician who elects to use paroxetine the efficacy of paroxetine was established in three 1 to 12 week trials in panic disorder patients whose diagnoses corresponded to the dsm iiir category of panic disorder see clinical pharmacology clinical trials panic disorder dsm iv is characterized by recurrent unexpected panic attacks i e a discrete period of intense fear or discomfort in which 4 or more of the following symptoms develop abruptly and reach a peak within 1 minutes 1 palpitations pounding heart or accelerated heart rate 2 sweating 3 trembling or shaking 4 sensations of shortness of breath or smothering 5 feeling of choking 6 chest pain or discomfort 7 nausea or abdominal distress 8 feeling dizzy unsteady lightheaded or faint 9 derealization feelings of unreality or depersonalization being detached from oneself 1 fear of losing control 11 fear of dying 12 paresthesias numbness or tingling sensations 13 chills or hot flushes long term maintenance of efficacy was demonstrated in a 3 month relapse prevention trial in this trial patients with panic disorder assigned to paroxetine demonstrated a lower relapse rate compared to patients on placebo see clinical pharmacology clinical trials nevertheless the physician who prescribes paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient the efficacy of paroxetine was established in three 12 week trials in adult patients with social anxiety disorder dsm iv paroxetine has not been studied in children or adolescents with social phobia see clinical pharmacology clinical trials the effectiveness of paroxetine in long term treatment of social anxiety disorder i e for more than 12 weeks has not been systematically evaluated in adequate and well controlled trials therefore the physician who elects to prescribe paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration the efficacy of paroxetine in the treatment of gad was established in two 8 week placebo controlled trials in adults with gad paroxetine has not been studied in children or adolescents with generalized anxiety disorder see clinical pharmacology clinical trials generalized anxiety disorder dsm iv is characterized by excessive anxiety and worry apprehensive expectation that is persistent for at least 6 months and which the person finds difficult to control it must be associated with at least 3 of the following 6 symptoms restlessness or feeling keyed up or on edge being easily fatigued difficulty concentrating or mind going blank irritability muscle tension sleep disturbance the efficacy of paroxetine in maintaining a response in patients with generalized anxiety disorder who responded during an 8 week acute treatment phase while taking paroxetine and were then observed for relapse during a period of up to 24 weeks was demonstrated in a placebo controlled trial see clinical pharmacology clinical trials nevertheless the physician who elects to use paroxetine for extended periods should periodically re evaluate the long term usefulness of the drug for the individual patient see dosage and administration
Leoni Bücken
2021-06-21T07:40:41.205Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-21T07:40:41.205Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-21T07:40:41.205Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-21T07:40:41.205Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-21T07:40:41.205Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-21T07:40:41.205Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
Leoni Bücken
2021-06-21T07:40:41.205Z